New mRNA flu shots enter human testing – could they beat the old ones?
NCT ID NCT07204964
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests several new mRNA-based flu vaccines in about 971 healthy adults aged 18 and older. The goal is to see how well they trigger an immune response and how safe they are compared to standard flu shots. Participants receive one dose of an experimental vaccine or a comparator, and researchers monitor side effects and antibody levels over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mRNA-based seasonal influenza vaccine candidates (Flu mRNA Formulations A, B1, B3)
What this could lead to
If successful, this could lead to more effective and faster-to-update seasonal flu vaccines for adults.
What could go wrong
This is an early phase 2a study, so the vaccines may not prove more effective than current options. Side effects like injection site pain or fever are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA, HUMAN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Guntersville, Alabama, 35976, United States
-
GSK Investigational Site
Canoga Park, California, 91303, United States
-
GSK Investigational Site
Walnut Creek, California, 94598, United States
-
GSK Investigational Site
Hialeah, Florida, 33012, United States
-
GSK Investigational Site
Miami, Florida, 33186, United States
-
GSK Investigational Site
Pembroke Pines, Florida, 33025, United States
-
GSK Investigational Site
Stockbridge, Georgia, 30281, United States
-
GSK Investigational Site
Carson City, Nevada, 89706, United States
-
GSK Investigational Site
Las Vegas, Nevada, 89109, United States
-
GSK Investigational Site
Greensboro, North Carolina, 27408, United States
-
GSK Investigational Site
North Charleston, South Carolina, 29405, United States
-
GSK Investigational Site
Austin, Texas, 78705, United States
-
GSK Investigational Site
Garland, Texas, 75043, United States
-
GSK Investigational Site
Newport News, Virginia, 23606, United States
-
GSK Investigational Site
Seattle, Washington, 98104, United States
-
GSK Investigational Site
Edegem, 2650, Belgium
-
GSK Investigational Site
Ghent, 9000, Belgium